
Claims

- 1. A staple oligonucleotide which is a single-stranded oligonucleotide comprising a 5'-end sequence, an intermediate sequence and a 3'-end sequence, the 5'-end sequence having a reverse complementarity with the intermediate sequence, the 3'-end sequence having a reverse complementarity with the intermediate sequence and the intermediate sequence having loops at both ends, the loops each comprising three to ten nucleotides and not forming a complementary bond intermolecularly.
- 2. The staple oligonucleotide according to claim 1, wherein the single-stranded oligonucleotide comprises 30 to 70 nucleotides in length.
- 3. The staple oligonucleotide according to claim 1 or 2, wherein the single-stranded oligonucleotide comprises 34 to 64 nucleotides in length.
- 4. The staple oligonucleotide according to any one of claims 1 to 3, wherein the single-stranded oligonucleotide comprises 38 to 58 nucleotides in length.
- 5. The staple oligonucleotide according to any one of claims 1 to 4, wherein the single-stranded oligonucleotide comprises 42 to 54 nucleotides in length.
- 6. The staple oligonucleotide according to any one of claims 1 to 5, wherein the loops each comprise 4 to 6 nucleotides in length.

- 7. The staple oligonucleotide according to any one of claims 1 to 6, wherein the single-stranded oligonucleotide comprises 42 to 54 nucleotides in length, and the loops each comprise 4 to 6 nucleotides in length.
- 8. The staple oligonucleotide according to any one of claims 1 to 7, wherein the oligonucleotide is a DNA or a DNA derivative.
- 9. The staple oligonucleotide according to any one of claims 1 to 8, whose phosphate groups are not phosphorothioated.
- 10. The staple oligonucleotide according to any one of claims 1 to 9, which is one selected from the group consisting of oligodeoxynucleotides of Sequence No. 1 to 3 of Sequence Listing, or an oligodeoxynucleotide represented by the following structural formula:



wherein the vertical lines mean a non-binding site (5') end and 3' end).

- 11. A medicament comprising the staple $\label{eq:condition} \mbox{oligonucleotide according to any one of claims 1 to 10.}$
- 12. The medicament according to claim 11, which is a transcription factor inhibitor, an antisense or an siRNA.
- 13. The medicament according to claim 12, wherein the transcription factor inhibitor is an antagonistic inhibitor.
- 14. The medicament according to claim 12 or 13, wherein the transcription factor is one selected from the group consisting of NF-KB, STAT-1, STAT-2, STAT-3, STAT-4, STAT-5, STAT-6, GATA-3, AP-1, E2F, Ets and CRE.
- 15. The medicament according to any one of claims 12 to 14, which is an agent for preventing, treating or improving inflammation, an allergic disease, an autoimmune disease, a central disease, reperfusion injury in a ischaemic disease, worsened prognosis after organ transplantation or organ surgery, or restenosis after percutaneous transluminal coronary angioplasty (PTCA).
- 16. The medicament according to any one of claims 12 to 15, wherein the inflammation is arthritis, dermatitis, nephritis, hepatitis, renal failure, cystitis, prostatitis, urethritis, ulcerative colitis or Crohn disease.
- 17. The medicament according to claim 16, wherein the arthritis is chronic rheumatoid arthritis or osteoarthritis.
- 18. The medicament according to claim 16, wherein the dermatitis is atopic dermatitis, contact dermatitis, psoriasis, cutaneous ulcer or decubitus.

- 19. Use of the staple oligonucleotide according to any one of claims 1 to 10, for producing a transcription factor inhibitor, an antisense or an siRNA.
- 20. A method for preventing, treating or improving a disease against which a transcription factor inhibitor, an antisense or an siRNA is efficacious, the method comprises the step of administering, to a patient, a pharmacologically effective amount of the staple oligonucleotide according to any one of claims 1 to 10.